Collaboration of Intercell with PATH for the development of Intercell's Streptococcus pneumoniae vaccine

08-Sep-2006

Intercell and PATH, a USbased nonprofit organization dedicated to finding solutions for global health issues announced an agreement to advance the development of Intercell's Streptococcus pneumoniae vaccine.

Intercell will receive a total of USD 7.3 m during the first stage of the collaboration, with the potential for substantial additional funding during later development phases. Intercell and PATH are committed to work together towards the successful development of the vaccine in clinical trials leading to registration and market approval.

PATH will provide funding to support Intercell's ongoing Streptococcus pneumoniae (Pneumococcus) proteinbased vaccine development program, facilitating the completion of preclinical work. This program is derived from Intercell's proprietary antigen discovery technology, AIP®, and targets a major worldwide cause of pneumonia, bacterial sepsis and meningitis.

Under the terms of the collaboration, Intercell will develop the vaccine and make it available at an affordable cost for children in developing World countries at greatest need, where Pneumococcus is a major cause of infant and childhood mortality. Intercell retains all rights in developed countries for the childhood formulation of the pneumococcal vaccine and also retains as a key aim the rights for an adult formulation of the same product, designed to prevent pneumococcal infection in the elderly. According to the company, current vaccines on the market cover only a limited number of pneumococcal strains, especially outside the US, and also are not affordable to countries in the developing World.

https://www.bionity.com/en/news/57731/collaboration-of-intercell-with-path-for-the-development-of-intercell-s-streptococcus-pneumoniae-vaccine.html